利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

72 条记录 (耗时 0.054 秒)

    OPHTHALMIC FORMULATIONS
    2.
    发明申请
    OPHTHALMIC FORMULATIONS 有权
    眼科配方

    公开(公告)号：US20140271876A1

    公开(公告)日：2014-09-18

    申请号：US14211516

    申请日：2014-03-14

    申请人： INOTEK PHARMACEUTICALS CORPORATION

    发明人： William K. MCVICAR ,  Harun TAKRURI

    IPC分类号： A61K31/7076 ,  A61K31/5575 ,  A61K45/06 ,  A61K9/00

    CPC分类号： A61K31/7076 ,  A61K9/0048 ,  A61K9/10 ,  A61K31/14 ,  A61K31/5575 ,  A61K45/06 ,  A61K47/02 ,  A61K47/26 ,  A61K47/38 ,  A61K2300/00

    摘要： The present invention relates to an ophthalmic formulation which comprises a fine particle of Compound A in an aqueous suspension and a manufacturing process thereof. More specifically, the present invention relates to a topically applied ophthalmic aqueous suspension which is obtainable by suspending fine particles of Compound A in an aqueous vehicle containing a surfactant and boric acid. The invention also provides processes for making the ophthalmic formulations and to methods of use thereof.

    摘要翻译： 本发明涉及在水性悬浮液中含有化合物A的细颗粒的眼用制剂及其制造方法。 更具体地说，本发明涉及一种局部施用的眼用水性悬浮液，其通过将化合物A的细颗粒悬浮在含有表面活性剂和硼酸的水性载体中而获得。 本发明还提供了制备眼用制剂的方法及其使用方法。

    METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS
    3.
    发明申请
    METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS 审中-公开
    减少人体内压力的方法

    公开(公告)号：US20130217643A1

    公开(公告)日：2013-08-22

    申请号：US13855919

    申请日：2013-04-03

    申请人： INOTEK PHARMACEUTICALS CORPORATION

    发明人： Shikha BARMAN ,  Rudolf A. BAUMGARTNER

    IPC分类号： C07H19/16

    CPC分类号： C07H19/16 ,  A61K31/7076

    摘要： Provided herein are compounds of Formula I, compositions comprising an effective amount of a compound of Formula I, and methods for reducing intraocular pressure comprising administering an effective amount of compounds of Formula I to a subject in need thereof.

    摘要翻译： 本文提供式I化合物，包含有效量的式I化合物的组合物和降低眼内压的方法，其包括向有需要的受试者施用有效量的式I化合物。

    Indenoisoquinolinone analogs and methods of use thereof
    5.
    发明授权
    Indenoisoquinolinone analogs and methods of use thereof 失效
    茚并异喹啉酮类似物及其使用方法

    公开(公告)号：US08119654B2

    公开(公告)日：2012-02-21

    申请号：US12039611

    申请日：2008-02-28

    申请人： Prakash Jagtap ,  Duy-Phong Pham-Huu ,  Frederick Cohen ,  Xiaojing Wang

    发明人： Prakash Jagtap ,  Duy-Phong Pham-Huu ,  Frederick Cohen ,  Xiaojing Wang

    IPC分类号： A61K31/473 ,  C07D221/18

    CPC分类号： C07D221/18 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D491/04 ,  C07D491/10

    摘要： The present invention relates to Indenoisoquinolinone Analogs, compositions comprising an effective amount of an Indenoisoquinolinone Analog and methods for treating or preventing an inflammatory disease, a reperfusion injury, diabetes mellitus, a diabetic complication, reoxygenation injury resulting from organ transplantation, an ischemic condition, a neurodegenerative disease, renal failure, a vascular disease, a cardiovascular disease, cancer, a complication of prematurity, cardiomyopathy, retinopathy, nephropathy, neuropathy, erectile dysfunction or urinary incontinence, comprising administering to a subject in need thereof an effective amount of an Indenoisoquinolinone Analog.

    摘要翻译： 本发明涉及茚并异喹啉酮类似物，包含有效量的茚并异喹啉酮类似物和治疗或预防炎性疾病，再灌注损伤，糖尿病，糖尿病并发症，器官移植引起的再氧化损伤，缺血状况， 神经变性疾病，肾衰竭，血管疾病，心血管疾病，癌症，早产儿并发症，心肌病，视网膜病变，肾病，神经病，勃起功能障碍或尿失禁，包括向有需要的受试者施用有效量的茚并异喹啉酮类似物 。

    N-benzyl substituted pyridyl porphyrin compounds and methods of use thereof
    6.
    发明授权
    N-benzyl substituted pyridyl porphyrin compounds and methods of use thereof 失效
    N-苄基取代的吡啶基卟啉化合物及其使用方法

    公开(公告)号：US07642250B2

    公开(公告)日：2010-01-05

    申请号：US11528082

    申请日：2006-09-26

    申请人： William Williams

    发明人： William Williams

    IPC分类号： A61K38/02

    CPC分类号： C07F15/025 ,  C07D487/22

    摘要： The present invention relates to N-Benzyl-Substituted Pyridyl Porphyrin Compounds and compositions comprising an effective amount of N-Benzyl-Substituted Pyridyl Porphyrin Compounds. The N-Benzyl-Substituted Pyridyl Porphyrin Compounds include compounds of the following formula: wherein: M is Fe or Mn; f is 0 or 1; each R is independently —C(O)(amino acid residue) or —SO2(amino acid residue); and n is the number of counterions sufficient to balance the charges of the compound of Formula (A).

    摘要翻译： 本发明涉及N-苄基取代的吡啶基卟啉化合物和包含有效量的N-苄基取代的吡啶基卟啉化合物的组合物。 N-苄基取代的吡啶基卟啉化合物包括下式的化合物：其中：M是Fe或Mn; f为0或1; 每个R独立地为-C（O）（氨基酸残基）或-SO 2（氨基酸残基）; 和n是足以平衡式（A）化合物的电荷的抗衡离子的数目。

    Purine Derivatives as adenosine A1 receptor agonists and methods of use thereof
    7.
    发明授权
    Purine Derivatives as adenosine A1 receptor agonists and methods of use thereof 有权
    嘌呤衍生物作为腺苷A1受体激动剂及其使用方法

    公开(公告)号：US07423144B2

    公开(公告)日：2008-09-09

    申请号：US11137632

    申请日：2005-05-25

    申请人： Prakash Jagtap ,  Csaba Szabo ,  Andrew L. Salzman

    发明人： Prakash Jagtap ,  Csaba Szabo ,  Andrew L. Salzman

    IPC分类号： A61K31/7056 ,  A61K31/7076 ,  A61K31/708 ,  C07H16/167 ,  C07H16/173

    CPC分类号： C07H19/167 ,  C07D473/34 ,  C07H19/12

    摘要： The invention relates to Purine Derivatives; compositions comprising an effective amount of a Purine Derivative; and methods for reducing an animal's rate of metabolism, protecting an animal's heart against myocardial damage during cardioplegia; or for treating or preventing a cardiovascular disease, a neurological disorder, an ischemic condition, a reperfusion injury, obesity, a wasting disease, or diabetes, comprising administering an effective amount of a Purine Derivative to an animal in need thereof.

    摘要翻译： 本发明涉及嘌呤衍生物; 包含有效量的嘌呤衍生物的组合物; 以及降低动物代谢率的方法，保护动物的心脏免受心脏停搏期间的心肌损伤; 或用于治疗或预防心血管疾病，神经障碍，缺血状况，再灌注损伤，肥胖症，消耗性疾病或糖尿病，包括向有需要的动物施用有效量的嘌呤衍生物。